(7)Â
đź“ŠÂ Low Float: With only 5.24M shares outstanding, demand could surge.
GeoVax’s low float of approximately 5.24 million shares means there’s a limited supply available. When a company with such potential has a low float, it often leads to heightened demand, which can drive significant movements. As
more recognize the value GeoVax brings, the limited number of shares could become highly sought after. (3)
Â
🧬 Cutting-Edge Pipeline: From next-gen C0VlD-19 vaccines to cancer therapies, their innovations are unmatched.
GeoVax isn’t just a one-trick pony. Their pipeline includes next-generation C0VlD-19 vaccines, therapies for advanced head and neck cancer, and preventive vaccines for
diseases like Mpox, Ebola, Zika, and malaria. These are all high-impact areas where effective treatments are desperately needed. The company’s proprietary technology platforms give them a unique edge in developing solutions that could address these critical health challenges. (8)
Â
🏆 Major Wins: Secured a $24.4M BARDA award with potential to reach $45M.
Recently, GeoVax secured a
significant win with a $24.4 million BARDA award to advance its dual-antigen next-generation C0VlD-19 vaccine. This award could increase to as much as $45 million, providing a strong financial boost to their research and development efforts. Additionally, their partnership with Allucent for a Phase 2b clinical trial, valued at up to $388 million, underscores the substantial financial support and confidence in their vaccine portfolio. (8)
